{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:39Z","timestamp":1790790219043,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Natural Science Fund","award":["16ZR1400400"],"award-info":[{"award-number":["16ZR1400400"]}]},{"name":"Beijing Medical Health Foundation-Medicine Science Study","award":["YWJKJJHKYJJ-G17007"],"award-info":[{"award-number":["YWJKJJHKYJJ-G17007"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12876-019-0966-4","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T13:04:44Z","timestamp":1555419884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection"],"prefix":"10.1186","volume":"19","author":[{"given":"Yayun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianya","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"issue":"12","key":"966_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212\u20139.","journal-title":"Vaccine"},{"key":"966_CR2","first-page":"2094","volume":"380","author":"R Lozana","year":"2012","unstructured":"Lozana R, M N, K F, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2094\u2013128.","journal-title":"Lancet"},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","volume":"57","author":"EAftSot. L","year":"2012","unstructured":"EAftSot. L. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167\u201384.","journal-title":"J Hepatol"},{"key":"966_CR4","volume-title":"MH: M: AASLD guidelines for treatment of chronic hepatitis B","author":"T AN","year":"2015","unstructured":"AN T, HN B, Chang K-M, Hwang JP, Jonas MM. MH: M: AASLD guidelines for treatment of chronic hepatitis B, vol. 2015; 2015."},{"key":"966_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.coviro.2016.06.003","volume":"18","author":"M Levrero","year":"2016","unstructured":"Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when? Curr Opin Virol. 2016;18:135\u201343.","journal-title":"Curr Opin Virol"},{"issue":"4","key":"966_CR6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jhep.2016.05.043","volume":"65","author":"J Petersen","year":"2016","unstructured":"Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65(4):835\u201348.","journal-title":"J Hepatol"},{"issue":"9","key":"966_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.tim.2016.05.006","volume":"24","author":"C Shih","year":"2016","unstructured":"Shih C, Chou SF, Yang CC, Huang JY, Choijilsuren G, Jhou RS. Control and eradication strategies of hepatitis B virus. Trends Microbiol. 2016;24(9):739\u201349.","journal-title":"Trends Microbiol"},{"issue":"1","key":"966_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/hep.27849","volume":"62","author":"T Gustot","year":"2015","unstructured":"Gustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, et al. Clinical course of acute-on-chronic liver failure syndrome and effects on prognosis. Hepatology (Baltimore, Md). 2015;62(1):243\u201352.","journal-title":"Hepatology (Baltimore, Md)"},{"issue":"2","key":"966_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.20535","volume":"41","author":"M-C Rousselet","year":"2005","unstructured":"Rousselet M-C, Dupr\u00e9 F, Crou\u00e9 A, Bedossa P, Saint-Andr\u00e9 E-P, Cal\u00e8s P. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41(2):257\u201364.","journal-title":"Hepatology"},{"key":"966_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJM200102153440706","volume":"344","author":"AA Bravo","year":"2001","unstructured":"Bravo AA, Sheth SG. S. C: Liver biopsy. N Engl J Med. 2001;344:495\u2013500.","journal-title":"N Engl J Med"},{"key":"966_CR11","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1002\/hep.23571","volume":"51","author":"AJ Thompson","year":"2010","unstructured":"Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933\u201344.","journal-title":"Hepatology"},{"key":"966_CR12","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology. 2010;52:1232\u201341.","journal-title":"Hepatology"},{"key":"966_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1055\/s-2006-939751","volume":"26","author":"S Hadziyannis","year":"2006","unstructured":"Hadziyannis S, Papatheodoridis GV. Hepatitis B e antigen-negative chronic hepatitis: natural history and treatment. Semin Liver Dis. 2006;26:130\u201341.","journal-title":"Semin Liver Dis"},{"key":"966_CR14","first-page":"2005","volume":"7","author":"Q Su","year":"2001","unstructured":"Su Q, Wang SF, Chang T-E, Breitkreutz R, Hennig H, Takegoshi K, EL HSC. Circulating hepatitis B virus nucleic acids in chronic infection:representation of differently Polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res. 2001;7:2005\u201315.","journal-title":"Clin Cancer Res"},{"key":"966_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/infdis\/jiv397","volume":"213","author":"L Jansen","year":"2015","unstructured":"Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus Pregenomic RNA is present in Virions in plasma and is associated with a response to Pegylated interferon alfa-2a and Nucleos(t)ide analogues. J Infect Dis. 2015;213:224\u201332.","journal-title":"J Infect Dis"},{"key":"966_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/hep.27381","volume":"61","author":"F Bommel van","year":"2015","unstructured":"van Bommel F, Bartens A, Mysickova A, Hofmann J, Kruger DH, Berg T, Edelmann A. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66\u201376.","journal-title":"Hepatology"},{"issue":"4","key":"966_CR17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","volume":"65","author":"J Wang","year":"2016","unstructured":"Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, Zhang R, Chen R, Li T, Zhang T, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016;65(4):700\u201310.","journal-title":"J Hepatol"},{"key":"966_CR18","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2016.09.027","volume":"66","author":"S Augustin","year":"2017","unstructured":"Augustin S, Pons M, Genesca\u21d1 J. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:454\u201367.","journal-title":"J Hepatol"},{"key":"966_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0166-3542(94)90022-1","volume":"23","author":"HLA Janssen","year":"1994","unstructured":"Janssen HLA, Kerhof-Los CJ, Heijtink RA, Schalm SW. Measurement of HBsAg to monitor hepatitis B viral replication in patients on a-interferon therapy. Antivir Res. 1994;23:251\u20137.","journal-title":"Antivir Res"},{"key":"966_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/hep.23568","volume":"51","author":"VW Wong","year":"2010","unstructured":"Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL. Durability of Peginterferon alfa-2a treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:1945\u201353.","journal-title":"Hepatology"},{"issue":"2","key":"966_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jcv.2009.07.005","volume":"46","author":"P Tangkijvanich","year":"2009","unstructured":"Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to Peginterferon alfa-2b therapy in chronic hepatitis B. J Clin Virol. 2009;46(2):117\u201323.","journal-title":"J Clin Virol"},{"key":"966_CR22","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1111\/j.1365-2036.2010.04474.x","volume":"32","author":"HL Chan","year":"2010","unstructured":"Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2010;32:1323\u20135.","journal-title":"Aliment Pharmacol Ther"},{"key":"966_CR23","doi-asserted-by":"publisher","first-page":"S333","DOI":"10.1016\/S0168-8278(09)60919-3","volume":"50","author":"G Lau","year":"2009","unstructured":"Lau G, Marcellin P, B M. On treatment monitoring of HBsAg levels to predict response to peginterferon alfa-2a in patients with HBeAg-positive chronic hepatitis B. J Hepatol. 2009;50:S333.","journal-title":"J Hepatol"},{"key":"966_CR24","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","volume":"52","author":"V Rijckborst","year":"2010","unstructured":"Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454\u201361.","journal-title":"Hepatology"},{"key":"966_CR25","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/hep.22744","volume":"49","author":"R Moucari","year":"2009","unstructured":"Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology. 2009;49:1151\u20137.","journal-title":"Hepatology"},{"issue":"5","key":"966_CR26","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","volume":"61","author":"HL A Janssen","year":"2012","unstructured":"A Janssen HL, Sonneveld MJ, MR B. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut. 2012;61(5):641\u20135.","journal-title":"Gut"},{"issue":"2","key":"966_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12664-013-0395-1","volume":"33","author":"J Ramachandran","year":"2014","unstructured":"Ramachandran J, Ismail AM, Chawla G, Fletcher GJ, Goel A, Eapen CE, Abraham P. Serum HBsAg quantification in treatment-naive Indian patients with chronic hepatitis B. Indian J Gastroenterol. 2014;33(2):131\u20135.","journal-title":"Indian J Gastroenterol"},{"issue":"27","key":"966_CR28","first-page":"9178","volume":"20","author":"LY Zeng","year":"2014","unstructured":"Zeng LY, Lian JS, Chen JY, Jia HY, Zhang YM, Xiang DR, Yu L, Hu JH, Lu YF, Zheng L, et al. Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study. World J Gastroenterol. 2014;20(27):9178\u201384.","journal-title":"World J Gastroenterol"},{"issue":"11\u201312","key":"966_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/j.1365-2036.2011.04888.x","volume":"34","author":"JW Jang","year":"2011","unstructured":"Jang JW, Yoo SH, Kwon JH, You CR, Lee S, Lee JH, Chung KW. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther. 2011;34(11\u201312):1337\u201346.","journal-title":"Aliment Pharmacol Ther"},{"key":"966_CR30","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479-480","author":"C Seeger","year":"2015","unstructured":"Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479-480:672\u201386.","journal-title":"Virology"},{"key":"966_CR31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/135965350901400208","volume":"14","author":"N Warner","year":"2009","unstructured":"Warner N, Locarnini S. Can antiviral therapy for chronic hepatitis B enhance the progression to hepatocellular carcinoma? Antivir Ther. 2009;14:139\u201342.","journal-title":"Antivir Ther"},{"key":"966_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/jhep.2002.34294","volume":"36","author":"RP Perrillo","year":"2002","unstructured":"Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002;36:186\u201394.","journal-title":"Hepatology"},{"key":"966_CR33","doi-asserted-by":"crossref","unstructured":"Norah A. Terrault, Natalie H. Bzowej, Kyong-Mi Chang, Jessica P. Hwang, Maureen M. Jonas, Murad6 MH: AASLD Guidelines for Treatment of Chronic Hepatitis B. 2015.","DOI":"10.1002\/hep.28156"},{"issue":"21","key":"966_CR34","doi-asserted-by":"publisher","first-page":"11577","DOI":"10.1128\/JVI.01414-07","volume":"81","author":"TM Abraham","year":"2007","unstructured":"Abraham TM, Loeb DD. The topology of hepatitis B virus pregenomic RNA promotes its replication. J Virol. 2007;81(21):11577\u201384.","journal-title":"J Virol"},{"key":"966_CR35","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","volume":"48","author":"M Tsuge","year":"2013","unstructured":"Tsuge M, Murakami E, Imamura M, Abe H, Miki D, Hiraga N, Takahashi S, Ochi H, Nelson Hayes C, Chayama K. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients. J Gastroenterol. 2013;48:1188\u2013204.","journal-title":"J Gastroenterol"},{"key":"966_CR36","unstructured":"Wang J, Yu Y, Li G, Shen C, Meng Z, Zheng J, Jia Y, Chen S, Zhang X, Zhu M, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2017;S0168827817322614.\u00a0"},{"key":"966_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","volume":"99-100","author":"H Huang","year":"2018","unstructured":"Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, Xu D, Lu F. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol. 2018;99-100:71\u20138.","journal-title":"J Clin Virol"},{"key":"966_CR38","doi-asserted-by":"crossref","unstructured":"Butler EK, Gersch J, McNamara A, Luk KC, Holzmayer V, de Medina M, Schiff E, Kuhns M, Cloherty GA. HBV serum DNA and RNA levels in nucleos(t)ide analogue-treated or untreated patients during chronic and acute infection. Hepatology. 2018;68(6):2106\u20132117.","DOI":"10.1002\/hep.30082"},{"issue":"3","key":"966_CR39","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1128\/JCM.05853-11","volume":"50","author":"Z Cui","year":"2012","unstructured":"Cui Z, Wang Y, Fang L, Zheng R, Huang X, Liu X, Zhang G, Rui D, Ju J, Hu Z. Novel real-time simultaneous amplification and testing method to accurately and rapidly detect mycobacterium tuberculosis complex. J Clin Microbiol. 2012;50(3):646\u201350.","journal-title":"J Clin Microbiol"},{"key":"966_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jviromet.2013.11.003","volume":"196","author":"Q Chen","year":"2014","unstructured":"Chen Q, Hu Z, Zhang Q, Yu M. Development and evaluation of a real-time method of simultaneous amplification and testing of enterovirus 71 incorporating a RNA internal control system. J Virol Methods. 2014;196:139\u201344.","journal-title":"J Virol Methods"},{"issue":"3","key":"966_CR41","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cld.2013.05.006","volume":"17","author":"M Martinot-Peignoux","year":"2013","unstructured":"Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to predict natural history and treatment outcome in chronic hepatitis B patients. Clin Liver Dis. 2013;17(3):399\u2013412.","journal-title":"Clin Liver Dis"},{"issue":"2","key":"966_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0168-8278(01)00266-5","volume":"36","author":"MR Brunetto","year":"2002","unstructured":"Brunetto MR, Oliveri F, Coco B. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002;36(2):263\u201370.","journal-title":"J Hepatol"},{"issue":"5","key":"966_CR43","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/hep.22518","volume":"48","author":"GV Papatheodoridis","year":"2008","unstructured":"Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection? Hepatology. 2008;48(5):1451\u20139.","journal-title":"Hepatology"},{"issue":"4","key":"966_CR44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0168-8278(02)00004-1","volume":"36","author":"M Martinotpeignoux","year":"2002","unstructured":"Martinotpeignoux M, Boyer N, Colombat M, Akremi R, Pham BN, Ollivier S, Castelnau C, Valla D, Degott C, Marcellin P. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol. 2002;36(4):543\u20136.","journal-title":"J Hepatol"},{"issue":"4","key":"966_CR45","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/hep.23803","volume":"52","author":"LY Chan","year":"2010","unstructured":"Chan LY, Wong WS, Wong LH, Tse CH, Chan HY, Sung JY. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52(4):1232\u201341.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"966_CR46","first-page":"S144","volume":"54","author":"LY Chan","year":"2011","unstructured":"Chan LY, Wong LH, Tse CH, Chan HY, Wong WS. Definition of inactive hepatitis B carrier by serum HBsAg and HBV DNA levlels-a long-term follow-up study on HBsAg seroclearance. J Hepatol. 2011;54(Suppl 1):S144\u20135.","journal-title":"J Hepatol"},{"issue":"5","key":"966_CR47","first-page":"S","volume":"52","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Moucari R, Leclere L, Cardoso AC, Carvalho R, Boyer N, Ripault MP, Asselah T, Marcellin P. Quantitative HBsAg:A new specific marker for the diagnosis of HBsAg inactive carriage. J Hepatol. 2010;52(5):S\u2013830-S-830.","journal-title":"J Hepatol"},{"issue":"5","key":"966_CR48","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1478-3231.2011.02693.x","volume":"32","author":"H Park","year":"2012","unstructured":"Park H, Lee JM, Seo JH, Kim HS, Ahn SH, Kim DY, Han KH, Chon CY, Park JY. Predictive value of HBsAg quantification for determining the clinical course of genotype C HBeAg-negative carriers. Liver Int. 2012;32(5):796\u2013802.","journal-title":"Liver Int"}],"updated-by":[{"DOI":"10.1186\/s12876-019-0991-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000}}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-019-0966-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-019-0966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T02:19:59Z","timestamp":1663294799000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-019-0966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1186\/s12876-019-0966-4","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2019","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1]","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of Changhai Hospital. (CHEC2017\u2013118) and also registered on the website:\u00a0ClinicalTrials.gov (NCT03909191).Written informed consent was obtained fromall the study participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"53"}}